Add Formweb to your mobile device
Brand name products with an equivalent generic may not be available to order at Henry Ford Health. For questions, contact inpatient pharmacy.
Approved Enterprise Formulary
Search results for:
risperiDONE
risperiDONE
| Drug Name | Form | Strength | Ambulatory Use Only | Ambulatory Restrictions | Inpatient Restrictions | Non-Formulary |
|---|---|---|---|---|---|---|
| RisperDAL Consta | POWDER FOR INJECTION, EXTENDED RELEASE, INTRAMUSCULAR | 12.5 mg/2 weeks; 25 mg/2 weeks; 37.5 mg/2 weeks; 50 mg/2 weeks | ||||
| Perseris | POWDER FOR INJECTION, EXTENDED RELEASE, SUBCUTANEOUS | 90 mg/month ; 120 mg/month | ||||
| RisperiDONE | SOLUTION, ORAL | 1 mg/mL | ||||
| Uzedy | SUSPENSION, EXTENDED RELEASE, SUBCUTANEOUS | 100 mg/0.28 mL; 125 mg/0.35 mL; 200 mg/0.56 mL; 250 mg/0.7 mL | ||||
| RisperiDONE | TABLET, DISINTEGRATING, ORAL | 0.5 mg; 1 mg; 2 mg; 3 mg | ||||
| RisperDAL M-Tab | TABLET, DISINTEGRATING, ORAL | 1 mg | ||||
| RisperDAL | TABLET, ORAL | 0.25 mg; 1 mg; 3 mg | ||||
| RisperiDONE | TABLET, ORAL | 0.5 mg; 0.25 mg; 1 mg; 2 mg; 3 mg |
VIEW MORE psychotherapeutic agents, antipsychotics, atypical antipsychotics
CLASS
CLASS
m00242, m00251, m00341
Last updated: Feb. 5, 2024
- Black Box Warning Elderly patients with dementia related psychosis
- Hazardous Drugs January 10th, 2019 NIOSH has determined it is unlikely that risperidone (Risperidal®) poses a carcinogenic, reproductive, or developmental hazard to workers in a healthcare setting and is no longer considered a hazardous drug by NIOSH.
- Look Alike Sound Alike Do Not Confuse risperiDONE with rOPINIRole.
- Policy Tier 1: Long Acting Injectable Antipsychotics
**Risperdal Consta is approved for use in the outpatient setting. Inpatient use restricted and must meet Tier 1 criteria**